Latest Insider Transactions at G1 Therapeutics, Inc. (GTHX)
This section provides a real-time view of insider transactions for G1 Therapeutics, Inc. (GTHX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of G1 Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of G1 Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2023
|
John V. Umstead Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+45.92%
|
-
|
|
Jan 05
2023
|
James S. Hanson General Counsel |
SELL
Open market or private sale
|
Direct |
729
-1.74%
|
$3,645
$5.41 P/Share
|
|
Jan 05
2023
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
729
-0.7%
|
$3,645
$5.41 P/Share
|
|
Jan 05
2023
|
Terry L Murdock Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
729
-1.96%
|
$3,645
$5.41 P/Share
|
|
Jan 05
2023
|
Jennifer K. Moses CFO |
SELL
Open market or private sale
|
Direct |
729
-1.25%
|
$3,645
$5.41 P/Share
|
|
Jan 04
2023
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Open market or private sale
|
Direct |
5,607
-1.99%
|
$28,035
$5.58 P/Share
|
|
Jan 04
2023
|
James S. Hanson General Counsel |
SELL
Open market or private sale
|
Direct |
1,639
-3.77%
|
$8,195
$5.58 P/Share
|
|
Jan 04
2023
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,639
-1.56%
|
$8,195
$5.58 P/Share
|
|
Jan 04
2023
|
Andrew Perry Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
820
-3.71%
|
$4,100
$5.58 P/Share
|
|
Jan 04
2023
|
Terry L Murdock Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,639
-4.22%
|
$8,195
$5.58 P/Share
|
|
Jan 04
2023
|
Jennifer K. Moses CFO |
SELL
Open market or private sale
|
Direct |
1,639
-2.72%
|
$8,195
$5.58 P/Share
|
|
Jan 03
2023
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Open market or private sale
|
Direct |
32,019
-10.2%
|
$160,095
$5.85 P/Share
|
|
Jan 03
2023
|
John E. (Jack) Bailey Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
80,700
+20.45%
|
-
|
|
Jan 03
2023
|
James S. Hanson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
17,900
+29.17%
|
-
|
|
Jan 03
2023
|
Mark Avagliano Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,600
+32.83%
|
-
|
|
Jan 03
2023
|
Rajesh Malik Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,900
+14.55%
|
-
|
|
Jan 03
2023
|
Andrew Perry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,100
+42.12%
|
-
|
|
Jan 03
2023
|
Terry L Murdock Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,900
+31.57%
|
-
|
|
Jan 03
2023
|
Jennifer K. Moses CFO |
BUY
Grant, award, or other acquisition
|
Direct |
22,300
+27.03%
|
-
|
|
Dec 15
2022
|
Rajesh Malik Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,000
+13.83%
|
$0
$0.3 P/Share
|
|
Oct 18
2022
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
15,000
-11.45%
|
$165,000
$11.7 P/Share
|
|
Oct 18
2022
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+10.27%
|
$0
$0.39 P/Share
|
|
Sep 20
2022
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
20,000
-14.71%
|
$260,000
$13.5 P/Share
|
|
Sep 20
2022
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+12.82%
|
$0
$0.39 P/Share
|
|
Sep 13
2022
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,000
-19.74%
|
$270,000
$15.71 P/Share
|
|
Sep 13
2022
|
Rajesh Malik Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,000
+16.48%
|
$0
$0.39 P/Share
|
|
Aug 16
2022
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
80,000
-40.82%
|
$960,000
$12.64 P/Share
|
|
Aug 16
2022
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
80,000
+28.99%
|
$0
$0.39 P/Share
|
|
Jul 05
2022
|
Terry L Murdock Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
648
-3.01%
|
$3,240
$5.17 P/Share
|
|
Jul 05
2022
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
648
-0.88%
|
$3,240
$5.17 P/Share
|
|
Jun 23
2022
|
Glenn P Muir |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+5.12%
|
-
|
|
Jun 23
2022
|
Cynthia Schwalm |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+38.63%
|
-
|
|
Jun 23
2022
|
Willie A Deese |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+41.0%
|
-
|
|
Jun 23
2022
|
Garry A Nicholson |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+41.0%
|
-
|
|
Jun 23
2022
|
Alicia Secor |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Feb 07
2022
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+11.45%
|
$0
$0.39 P/Share
|
|
Feb 01
2022
|
Rajesh Malik Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.93%
|
$0
$0.3 P/Share
|
|
Feb 01
2022
|
Jennifer K. Moses CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,333
+2.97%
|
$6,999
$3.95 P/Share
|
|
Jan 05
2022
|
Mark Avagliano Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,445
-6.28%
|
$14,450
$10.61 P/Share
|
|
Jan 05
2022
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,445
-2.21%
|
$14,450
$10.61 P/Share
|
|
Jan 05
2022
|
Jennifer K. Moses CFO |
SELL
Open market or private sale
|
Direct |
1,445
-3.91%
|
$14,450
$10.61 P/Share
|
|
Jan 05
2022
|
Terry L Murdock Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,445
-6.28%
|
$14,450
$10.61 P/Share
|
|
Jan 05
2022
|
James S. Hanson General Counsel |
SELL
Open market or private sale
|
Direct |
1,445
-5.35%
|
$14,450
$10.61 P/Share
|
|
Jan 03
2022
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Open market or private sale
|
Direct |
34,125
-12.77%
|
$341,250
$10.41 P/Share
|
|
Jan 03
2022
|
John E. (Jack) Bailey Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
46,000
+14.68%
|
-
|
|
Jan 03
2022
|
Mark Avagliano Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+34.29%
|
-
|
|
Jan 03
2022
|
Rajesh Malik Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+15.52%
|
-
|
|
Jan 03
2022
|
Jennifer K. Moses CFO |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+24.49%
|
-
|
|
Jan 03
2022
|
Terry L Murdock Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+34.29%
|
-
|
|
Jan 03
2022
|
Andrew Perry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+49.92%
|
-
|